WallStSmart

JBS N.V. (JBS)vsThe Marzetti Company (MZTI)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

JBS N.V. generates 4227% more annual revenue ($84.15B vs $1.94B). MZTI leads profitability with a 9.3% profit margin vs 2.5%. JBS trades at a lower P/E of 14.5x. MZTI earns a higher WallStSmart Score of 51/100 (C-).

JBS

Buy

51

out of 100

Grade: C-

Growth: 4.0Profit: 6.0Value: 5.7Quality: 5.5
Piotroski: 4/9Altman Z: 2.40

MZTI

Buy

51

out of 100

Grade: C-

Growth: 5.3Profit: 7.0Value: 4.7Quality: 8.0
Piotroski: 2/9Altman Z: 6.28
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

JBSSignificantly Overvalued (-132.0%)

Margin of Safety

-132.0%

Fair Value

$7.00

Current Price

$15.03

$8.03 premium

UndervaluedFair: $7.00Overvalued
MZTISignificantly Overvalued (-74.5%)

Margin of Safety

-74.5%

Fair Value

$89.47

Current Price

$141.76

$52.29 premium

UndervaluedFair: $89.47Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

JBS3 strengths · Avg: 8.3/10
Return on EquityProfitability
24.1%9/10

Every $100 of equity generates 24 in profit

P/E RatioValuation
14.5x8/10

Attractively priced relative to earnings

Price/BookValuation
1.9x8/10

Reasonable price relative to book value

MZTI3 strengths · Avg: 9.3/10
Debt/EquityHealth
0.0810/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
6.2810/10

Safe zone — low bankruptcy risk

Revenue GrowthGrowth
20.2%8/10

Revenue surging 20.2% year-over-year

Areas to Watch

JBS3 concerns · Avg: 2.0/10
Profit MarginProfitability
2.5%3/10

2.5% margin — thin

EPS GrowthGrowth
-16.2%2/10

Earnings declined 16.2%

Debt/EquityHealth
2.561/10

Elevated debt levels

MZTI3 concerns · Avg: 3.0/10
EPS GrowthGrowth
4.3%4/10

4.3% earnings growth

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

PEG RatioValuation
3.122/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : JBS

The strongest argument for JBS centers on Return on Equity, P/E Ratio, Price/Book. Revenue growth of 13.4% demonstrates continued momentum.

Bull Case : MZTI

The strongest argument for MZTI centers on Debt/Equity, Altman Z-Score, Revenue Growth. Revenue growth of 20.2% demonstrates continued momentum.

Bear Case : JBS

The primary concerns for JBS are Profit Margin, EPS Growth, Debt/Equity. Debt-to-equity of 2.56 is elevated, increasing financial risk. Thin 2.5% margins leave little buffer for downturns.

Bear Case : MZTI

The primary concerns for MZTI are EPS Growth, Piotroski F-Score, PEG Ratio.

Key Dynamics to Monitor

JBS profiles as a value stock while MZTI is a growth play — different risk/reward profiles.

MZTI is growing revenue faster at 20.2% — sustainability is the question.

JBS generates stronger free cash flow (543M), providing more financial flexibility.

Monitor PACKAGED FOODS industry trends, competitive dynamics, and regulatory changes.

Bottom Line

JBS scores higher overall (51/100 vs 51/100) and 13.4% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

JBS N.V.

CONSUMER DEFENSIVE · PACKAGED FOODS · USA

JBS N.V., is a protein and food company globally. The company is headquartered in Amstelveen, Netherlands.

The Marzetti Company

CONSUMER DEFENSIVE · PACKAGED FOODS · USA

The Marzetti Company engages in the manufacturing and marketing of specialty food products for the retail and foodservice channels in the United States. The company is headquartered in Westerville, Ohio.

Visit Website →

Want to dig deeper into these stocks?